The effects of anti-EGFR therapy in the setting of resectable metastases, such as tumor sidedness, RAF mutation, HER2 amplification, and microsatellite instability status, which were untested at the time of trial enrolment as the knowledge of resistance to anti-EGFR antibodies, post-date the design of this trial [35]. This evidence concerns the gene EGFR and neoplasm.